Search clinical trials for: Combivent® CFC inhalation aerosol

Total 239 results

Boehringer Ingelheim

Terminated

Combivent® HFA-propelled Compared to CFC-propelled Metered Dose Inhaler in Patients With COPD (Chronic Obstructive Pulmonary Disease)

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

A Confirmation Study of Combivent HFA Inhalation Aerosol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Terminated

Comparison of Safety and Efficacy of COMBIVENT HFA to COMBIVENT (CFC) in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Safety and Tolerability of COMBIVENT® HFA as Compared to COMBIVENT® CFC and Placebo HFA in Healthy Male and Female Subjects

Healthy
The First Affiliated Hospital of Soochow University

Recruiting

The Effect of Precise Aerosol Inhalation Nursing on Sputum Excretion in Elderly Patients With Lung Surgery

Inhalation

China
University of Roma La Sapienza
Queen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention Srl

Completed

Sulfureous Water Therapy in Viral Respiratory Diseases (STWandRVD)

Post Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 Syndrome

Italy
Amphastar Pharmaceuticals, Inc.

Terminated

Randomized, Placebo/Active Crossover Dose-ranging Study for Safety and Efficacy in Asthma Patients.

Asthma

United States
Boehringer Ingelheim

Completed

Study of the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to the Market Standard, Atrovent® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Clinical Study to Evaluate the Pharmacokinetics and Safety of BDP HFA Nasal Aerosol

Allergic Rhinitis
Amphastar Pharmaceuticals, Inc.

Completed

Epinephrine Inhalation Aerosol USP, a HFA-MDI Study for Assessment of Pharmacokinetics

Asthma | Shortness of Breath | Wheezing | Bronchospasm

United States
Boehringer Ingelheim

Completed

Ipratropium Bromide/Salbutamol Delivered by the Respimat® Inhaler Compared to Ipratropium Bromide Respimat®, COMBIVENT® Inhalation Aerosol and Placebo in Adults With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Trial to Determine the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to ATROVENT® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Amphastar Pharmaceuticals, Inc.

Terminated

Assessment and Evaluation of Pharmacokinetic Profile of E004 in Healthy Adults

Asthma

United States
Amphastar Pharmaceuticals, Inc.

Completed

Epinephrine Inhalation Aerosol USP: For Evaluation Of Efficacy And Safety In Asthma Patients

Asthma

United States
Cipla Ltd.

Not yet recruiting

BE Study of Albuterol Sulfate Inhalation Aerosol 90 mcg Per Actuation in Patients With Stable Mild Asthma

Bronchial Asthma

United States
Boehringer Ingelheim

Completed

Efficacy and Safety of Tiotropium Compared to Salmeterol and Placebo in Patients With Chronic Obstructive Bronchitis (COPD)

Pulmonary Disease, Chronic Obstructive
Sunovion

Terminated

A Study of Levalbuterol Tartrate HFA Inhalation Aerosol Metered Dose Inhaler (MDI) in Pediatric Subjects

Asthma

United States
Boehringer Ingelheim

Completed

4 Week 2 Way Crossover Double Blind Treatment Phase With Combivent CFC Versus Albuterol Followed by a 4 Week Open Label Combivent Respimat When All Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma

Asthma

United States
GlaxoSmithKline

Completed

ELLIPTA™ vs. MDI Inhaler Preference Study, in Adult Subjects With Asthma

Asthma

United States
Pearl Therapeutics, Inc.

Completed

Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD (telos)

Chronic Obstructive Pulmonary Disorder

United States, Canada, Germany, Hungary, Korea, Republic of, Poland, Russian Federation, Czechia
Neutec Ar-Ge San ve Tic A.Ş

Withdrawn

Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD

Chronic Obstructive Pulmonary Disease
Genomictree, Inc.
Samsung Medical Center; Pusan National University Hospital; Asan Medical Center; Seoul National University Hospital and other collaborators

Recruiting

A Stool DNA-based SDC2 Methylation Test for the Early Detection of Colorectal Cancer

Colorectal Cancer | Advanced Colorectal Neoplasm | Advanced Adenomas | Non-neoplastic Polyps | Non-advanced Adenomas

Korea, Republic of
Bio Products Laboratory

Completed

A Study to Compare the Pharmacokinetics and Safety of Current Factor VIII Concentrate and Optivate® in Haemophilia A.

Von Willebrand Disease

Poland, United Kingdom
LEO Pharma

Completed

A Psoriasis Plaque Test Trial With LP0113 Spray in Patients With Psoriasis Vulgaris (LP0113-1123) (LP0113-1123)

Skin and Connective Tissue Diseases

France
Henan University of Traditional Chinese Medicine

Unknown

Effect of Acupuncture on Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

China
Sunovion

Completed

Evaluation of a Novel Questionnaire to Assess Patient Satisfaction With and Preference of Intranasal Corticosteroids for the Treatment of Allergic Rhinitis

Perennial Allergic Rhinitis

United States
Ola Blennow, MD, PhD
Karolinska University Hospital; Danderyd Hospital; Centrallasarettet Västerås

Active, not recruiting

Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19) (HALT)

Pneumonia, Viral | Covid-19 | Sars-CoV2

Sweden
Amphastar Pharmaceuticals, Inc.

Terminated

4-Week Study of Efficacy, Safety and PK of Albuterol-HFA Versus Proventil-HFA in Pediatric Asthma

Asthma

United States
Chiesi Farmaceutici S.p.A.

Completed

Study to Investigate the Pharmacokinetics of CHF 6001 DPI Administered Via Nexthaler® Device or the Capsule for Oral Inhalation Via Aerolizer® Device

COPD

Belgium
LEO Pharma

Completed

A Vasoconstriction Study With LEO 90100

Psoriasis Vulgaris

France
LEO Pharma

Completed

Patient Insights Following Use of LEO 90100 Aerosol Foam and Daivobet® Gel in Subjects With Psoriasis Vulgaris

Psoriasis Vulgaris

Canada
Pearl Therapeutics, Inc.

Completed

Pharmacokinetics and Safety Study of PT010 in Healthy Subjects

COPD

United States
Intech Biopharm Ltd.

Completed

Bioequivalence Between Albuterol Sulfate Inhalation Aerosol 108mcg Per Actuation and Proair HFA (Albuterol Sulfate) Inhalation Aerosol 90mcg Per Actuation in Healthy Volunteers Under Fasting Conditions

Healthy

Taiwan
Boehringer Ingelheim

Terminated

Efficacy and Safety of Combivent® Aerosol and Spacer, in Adult Patients With Moderate to Severe Asthma Crisis

Asthma
Astellas Pharma Inc
Astellas Pharma US, Inc.

Completed

A Study of the Safety and Efficacy of Tacrolimus Inhalation Aerosol in Subjects With Persistent Asthma

Asthma

United States
Boehringer Ingelheim

Completed

Combivent® CFC Metered Dose Inhaler (MDI) in Moderate to Severe Asthma

Asthma

United States
LEO Pharma

Completed

A Psoriasis Plaque Test Trial With LEO 90100 Compared to Betesil® in Patients With Psoriasis Vulgaris

Skin and Connective Tissue Diseases

France
Bitop AG

Active, not recruiting

Multicentre Post-market Study of Ectoin® Inhalation Solution in Treatment of Asthma. (EIL-AST)

Asthma

Poland
Mannkind Corporation

Completed

A Study Designed to Compare 2 Dose Strengths of TI Inhalation Powder in Adults With Type 1 Diabetes Mellitus and to Compare One of Those Formulations (30Units) With an Injection of Insulin Lispro

Diabetes Mellitus: Type 1

United States
Prof. Dr. Carsten Perka
Julius Wolff Institute

Unknown

In-vivo Comparison of Different Levels of Femoral Rollback in a Primary Total Knee Arthroplasty (DePuyAttune)

Gonarthrosis

Germany
Hospital Clinic of Barcelona

Completed

Chlorobutanol, Potassium Carbonate, and Irrigation in Cerumen Removal

Vertigo | Hearing Loss | Ear Infection

Spain
Zealand University Hospital

Completed

Treatment and Prevention of Middle Ear Morbidity in Head and Neck Cancer Patients Following Radiotherapy

Hearing Loss | Otitis Media With Effusion | Chronic Otitis Media
Catholic University of the Sacred Heart
ISS, Dip.Tecnologie e Salute, Prof. Gianfranco Donelli

Completed

Comparison of Central Venous Catheters With Silver Nanoparticles Versus Conventional Catheters (NanoAgCVC)

Central Venous Catheter Related Infections

Italy
Intech Biopharm Ltd.

Completed

Bioequivalence Between Albuterol Sulfate Inhalation Aerosol 108 mcg Per Actuation and Proair HFA (Albuterol Sulfate) Inhalation Aerosol 90 mcg Per Actuation in Healthy Volunteers Under Fasting Conditions

Healthy

Taiwan
Alcon, a Novartis Company

Completed

Femtosecond Laser Assisted Cataract Surgery in Intumescent Cataracts

Intumescent Cataract
Schön Klinik Berchtesgadener Land

Completed

Effects of an Oxymizer® During Daytime in Patients With Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis

Germany
West China Hospital
Peking Union Medical College Hospital

Unknown

The Effects of Anti-infective Central Venous Catheter on Catheter-related Infection in Critically Patients

Critical Illness

China
Amphastar Pharmaceuticals, Inc.

Completed

Epinephrine Inhalation Aerosol USP, CLINICAL STUDY-B3 FOR ASSESSMENT OF PHARMACOKINETICS

Asthma

United States
Windtree Therapeutics

Terminated

Trial To Assess The Safety And Tolerability Of Lucinactant For Inhalation In Preterm Neonates 26 to 28 Weeks PMA

Respiratory Distress Syndrome

Canada, United States, Chile, Poland
Pearl Therapeutics, Inc.

Completed

24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003, Open-Label Spiriva® Respimat® as an Active Control, and Placebo

COPD

3

Subscribe